Whitepaper

ASCO Reveals: Increasing Options For Relapse/ Refractory Patients In Haematological Malignancies
Hope for patients living with haematological malignancies; Immunotherapies represent a novel class of biologics
ASCO Reveals: Increasing Options for Relapse/ Refractory Patients in Haematological Malignancies

More Whitepapers / Newsletters

Prader-Willi Syndrome
Prader-Willi Syndrome

A complex genetic condition, Prader-Willi syndrome (PWS) is a result of the loss of the functioning of genes in a particular region of chromosome 15. Genetic testing confirms the definitive diagnosis...

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Blastic Plasmacytoid Dendritic...

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an extremely rare form of neoplasm, generally affects the elderly male population. Cancer develops in bone marrow and blood. It involves multiple...

Idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive form of interstitial lung disease (ILD), characterized by fibrosis and worsening lung function. It majorly affects the population older of...

Remdesivir In COVID-19
Remdesivir In COVID-19

Remdesivir is a broad-spectrum antiviral drug that has previously demonstrated in vitro and in vivo activity against the viral pathogens MERS and SARS, which are also coronaviruses having structural s...

Digital Therapeutics In Mental Health Whitepaper
Digital Therapeutics In Mental...

Digital therapies are evidence-based clinical approaches powered by software applications designed to prevent, control or treat a particular disease or condition. While advances in technology-assisted...